Pluri (PLUR) Income from Non-Controlling Interests (2015 - 2025)
Pluri (PLUR) posted quarterly Income from Non-Controlling Interests of -$329000.0 for Q4 2025, down 113.64% year-over-year from $2.4 million in Q4 2024, and down 16.67% quarter-over-quarter from -$282000.0 in Q3 2025.
Pluri (PLUR) Income from Non-Controlling Interests (2015 - 2025) Analysis & Trends
Pluri (PLUR) has reported Income from Non-Controlling Interests for 5 consecutive years, with -$329000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Non-Controlling Interests fell 113.64% year-over-year to -$329000.0; the TTM figure through Dec 2025 stood at -$970000.0 (down 80.3% YoY), while the FY2025 annual figure was -$667000.0, down 46.27% from the prior year.
- Income from Non-Controlling Interests fell to -$329000.0 in Q4 2025 per PLUR's latest filing, from -$282000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$53000.0 in Q1 2022 and bottomed at -$329000.0 in Q4 2025.
- Historically, Income from Non-Controlling Interests has averaged -$152000.0 across 4 years, with a median of -$142000.0 in 2022.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 35.04% in 2023 and fell as far as 152.83% in 2023.
- Pluri's Income from Non-Controlling Interests stood at -$137000.0 in 2022, then soared by 35.04% to -$89000.0 in 2023, then plunged by 73.03% to -$154000.0 in 2024, then plunged by 113.64% to -$329000.0 in 2025.
- Business Quant data shows PLUR's Income from Non-Controlling Interests at -$329000.0 in Q4 2025, -$282000.0 in Q3 2025, and -$171000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | -329,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -329,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Jun 30, 2025 | -171,000.00 |
| Mar 31, 2025 | -188,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Sep 30, 2024 | -154,000.00 |
| Jun 30, 2024 | -133,000.00 |
| Mar 31, 2024 | -97,000.00 |
| Dec 31, 2023 | -89,000.00 |
| Sep 30, 2023 | -137,000.00 |
| Jun 30, 2023 | -147,000.00 |
| Mar 31, 2023 | -134,000.00 |
| Dec 31, 2022 | -137,000.00 |
| Sep 30, 2022 | -148,000.00 |
| Jun 30, 2022 | -79,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Mar 31, 2015 | -70,000.00 |